Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
135
resultados
Última actualización
01/09/2024 [07:12:00]
Resultados 100 a 125 de 135
Resumen de: CN117843769A
The invention discloses preparation and application of a high-affinity scFv antibody for resisting an infectious bursal disease virus. The scFv antibody provided by the invention comprises a heavy chain variable region, a light chain variable region and a connecting region between the heavy chain variable region and the light chain variable region, eight scFv antibodies are screened by using an antigen-antibody co-expression bacterial display technology and have high affinity with IBDV VP2 protein and different IBDV virus strains, and the scFv antibodies with high affinity and neutralizing activity can be screened by constructing a mutant library and are used for preventing and treating IBD; the kit can also be used for detecting IBDV pathogens by an ELISA method.
Resumen de: CN117843771A
The invention discloses preparation and application of a high-affinity scFv antibody for resisting an infectious bursal disease virus. The scFv antibody provided by the invention comprises a heavy chain variable region, a light chain variable region and a connecting region between the heavy chain variable region and the light chain variable region, eight scFv antibodies are screened by using an antigen-antibody co-expression bacterial display technology and have high affinity with IBDV VP2 protein and different IBDV virus strains, and the scFv antibodies with high affinity and neutralizing activity can be screened by constructing a mutant library and are used for preventing and treating IBD; the kit can also be used for detecting IBDV pathogens by an ELISA method.
Resumen de: CN117843767A
The invention discloses preparation and application of a high-affinity scFv antibody for resisting an infectious bursal disease virus. The scFv antibody provided by the invention comprises a heavy chain variable region, a light chain variable region and a connecting region between the heavy chain variable region and the light chain variable region, eight scFv antibodies are screened by using an antigen-antibody co-expression bacterial display technology and have high affinity with IBDV VP2 protein and different IBDV virus strains, and the scFv antibodies with high affinity and neutralizing activity can be screened by constructing a mutant library and are used for preventing and treating IBD; the kit can also be used for detecting IBDV pathogens by an ELISA method.
Resumen de: CN117843768A
The invention discloses preparation and application of a high-affinity scFv antibody for resisting an infectious bursal disease virus. The scFv antibody provided by the invention comprises a heavy chain variable region, a light chain variable region and a connecting region between the heavy chain variable region and the light chain variable region, eight scFv antibodies are screened by using an antigen-antibody co-expression bacterial display technology and have high affinity with IBDV VP2 protein and different IBDV virus strains, and the scFv antibodies with high affinity and neutralizing activity can be screened by constructing a mutant library and are used for preventing and treating IBD; the kit can also be used for detecting IBDV pathogens by an ELISA method.
Resumen de: CN117821583A
The invention relates to a microbial marker for treating ulcerative colitis on the basis of coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker is at least one of the following microorganisms or any combination of the microorganisms: Bacteroides xylanisolvens, Dialister invirus, Neatibacillus faecipullorum, Alistis dispar, Fimiplasma intestinipullorum, Dysosmobacter welbiorum, Prevotella sterilis, Streptococcus pasteurianus, Bifidobacterium adolescents, B. The microbial marker is at least one of the following microorganisms: Bacteroides xylanisolvens, Dialister invirus, Neatibacillus faecipullorum, Alistis dispar, Dysosmobacter welbiorum, Prevotella sterilis, Streptococcus The method comprises the following steps: step 1, collecting original data; step 2, data quality control and host removal; step 3, sequence assembly; step 4, carrying out Binning box separation; step 5, Bin quantification and annotation; step 6, Guild clustering is carried out; step 7, Guild analysis is carried out, such that a microbial marker is obtained; and step 8, establishing a prediction model: evaluating the response capability of the microbial marker for distinguishing the states before and after FMT.
Resumen de: CN117821371A
The invention belongs to the technical field of medical detection, and discloses a rhesus monkey intestinal tract organ model construction and identification method, which comprises: S1, separating and obtaining monkey intestinal mucosa crypts; s2, culture and passage of monkey intestinal organs; s3, performing immunofluorescent staining identification on the intestinal organs. The form of the constructed rhesus monkey intestinal tract organoid is consistent with that of mouse intestinal tract organoid and human intestinal tract organoid reported in existing literatures, an immunofluorescence result shows that staining of intestinal tract stem cells, intestinal tract epithelial cells AldolaseB + AldolaseC, intestinal tract endocrine cells, panning cells and goblet cells in normal intestinal tract epithelial cell types is positive, and staining of the intestinal tract stem cells, the intestinal tract epithelial cells AldolaseB + AldolaseC, the intestinal tract endocrine cells, the panning cells and the goblet cells in the normal intestinal tract epithelial cell types is positive. It is indicated that the constructed intestinal tract organoid contains all intestinal epithelial cell types, the monkey normal intestinal tract organoid model is successfully constructed, and a new in-vitro experimental model is provided for mechanism research of intestinal tract diseases, especially inflammatory bowel diseases.
Resumen de: CN117825706A
The invention discloses a molecular marker for diagnosing an inflammatory bowel disease and application of the molecular marker, and the molecular marker for diagnosing the inflammatory bowel disease (IBD) is ribonuclease III (Ribonuclease III, RNASE3). The expression level of the RNASE3 protein in the colon of a mouse with DSS induced colitis is obviously higher than that of a control mouse, and the expression level is further confirmed in the colon of a clinical IBD patient. The method has the advantages that the expression quantity of the RNASE3 protein in the excrement of the mouse in the acute stage is the highest, and the expression quantity of the RNASE3 protein in the remission stage is reduced, so that the research finds that the RNASE3 is a potential biomarker of the IBD and has the characteristics of noninvasive property, sensitivity and the like.
Resumen de: CN117797246A
The invention provides an application of IL-28A in preparation of a medicine for treating colon cancer/colitis, and belongs to the technical field of biological medicine.In an AOM + DSS model, compared with a wild type mouse (IL-28AWT) group, colon tumors of IL-28A gene knockout (IL-28A-/-) mice grow more quickly, the number of the tumors is larger, and the colon cancer/colitis can be better treated. Meanwhile, whether the IL-28A has an inhibiting effect on the development of mouse colitis diseases or not is also researched, and the result shows that the IL-28A can inhibit acute enteritis of mice. Furthermore, the invention finds that IL-28A directly inhibits differentiation and recruitment of MDSCs by activating an IL-28A receptor expressed by MDSCs, and plays a key regulation role in occurrence and development of colon cancer. Therefore, the invention reveals that IL-28A can significantly inhibit colon cancer/colitis for the first time. The invention provides a new drug choice for clinical diagnosis and treatment of tumors.
Resumen de: CN117783540A
The invention discloses a marker for diagnosing irritable bowel syndrome (AIBS) accompanied with anxiety and depression symptoms. The marker is selected from one or more of FGA, RELN and TUBA1A. By measuring the expression quantities of FGA, RELN and TUBA1A proteins in serum of a patient, whether the IBS patient belongs to the AIBS subtype or not can be well predicted, the AIBS patient can be more accurately screened, and then the method has wide significance in adopting medicine intervention for regulating emotion or performing psychological counseling.
Resumen de: WO2024061978A1
The invention relates to a method for the diagnosis of ulcerative colitis in a subject by detecting a nucleic acid target region and to oligonucleotides, oligonucleotide probes and kits to be used in this method.
Resumen de: US2024101715A1
Provided are various embodiments relating to caninized TNFα antibodies and caninized NGF antibodies. Such antibodies can be used in methods to treat canines with inflammatory conditions, such as inflammatory bowel disease and/or in methods to treat canines with pain, such as osteoarthrititic pain, back pain, cancer pain, and/or a neuropathic pain.
Resumen de: US2024103008A1
The present disclosure provides matched gut and peripheral biomarkers to assess, identify and improve therapeutic measures for IBD, in particular ulcerative colitis and Crohn's disease.
Resumen de: EP4343001A1
The invention relates to a method for the diagnosis of ulcerative colitis in a subject by detecting a nucleic acid target region and to oligonucleotides, oligonucleotide probes and kits to be used in this method.
Resumen de: CN117120826A
The present disclosure provides methods for monitoring mucosal healing in a patient suffering from a digestive disease or for use in pre-disease states and including intestinal and parenteral disorders in which digestive tract permeability is increased. The method may include establishing a baseline of the patient, treating a digestive disease or a pre-disease state of the patient, measuring digestive tract permeability of the patient after treatment, and comparing a second total percentage of the recovered administered doses to the baseline total percentage of the recovered administered doses.
Resumen de: CN117741141A
The invention relates to the technical field of biological medicine, in particular to a system for judging DSS-induced ulcerative colitis based on peripheral blood T cell subsets and application of the system, and the system comprises a sample collecting and processing module which is set to obtain peripheral blood mononuclear cells; the detection module is set to identify and count the total number of CD45 + CD3 + T cells in the peripheral blood mononuclear cells obtained by the sample collecting and processing module, and divide and respectively count the cell numbers of the following cell subgroups: Th1, Th2, Th17, CD 8 + NK1. 1 + gamma delta T, CD62L + CD8 + T and NK1. 1 + CD8 + T to obtain the proportion of each cell subgroup; the prediction and judgment module is set to realize the following judgment: comparing the proportions of the cell subgroups with corresponding reference values respectively, and when the proportions of the Th2, Th17 and CD8 + NK1. 1 + gamma delta T cell subgroups are higher than the reference values; if the proportion of the cell subsets NK1, Th1, CD62L + CD8 + T and NK1. 1 + CD8 + T is lower than a reference value, the DSS-induced ulcerative colitis is prompted.
Resumen de: WO2024056027A1
The present invention provides use of an ldh gene-containing lactobacillus plantarum in preparing a product for relieving enteritis. The lactobacillus plantarum or plasmid involved in the present invention is an ldh gene-containing lactobacillus plantarum or plasmid. Experiments prove that the ldh gene has the function of preventing and relieving inflammation. According to the present invention, lactobacillus plantarum AR113 with acetate kinase (ackA), D-lactate dehydrogenase (D-ldh), and L-lactate dehydrogenase (L-ldh) knocked out is taken as a research object. By studying the effect of the knock-out strains on O157:H7-induced colitis, the important role of lactic acid in alleviating tissue damage caused by O157:H7 and protecting the integrity of intestinal epithelial cells is investigated, and lactic acid can effectively relive and prevent different types of enteritis; a lactic acid or a lactate dehydrogenase gene is selected as a screening marker for bacterium screening, and it is concluded that it is the lactic acid that plays a major relieving role in colitis, thereby laying a foundation for a method for screening probiotics with an inflammation relieving function.
Resumen de: US2024094202A1
Irritable Bowel Syndrome (IBS) is a multifactorial disorder characterized by pain, bloat, and changes in bowel movements, where different bacteria in the gut microbiome potentially influence some or all of the related symptoms. However, IBS is extremely heterogenous, suggesting a need to identify relationships between groups of bacteria in the gut microbiome and specific IBS-related symptoms. RS consumption significantly altered the microbiome while improving several measures of IBS. The use of RS by those needing to reduce the IBS-related symptoms, including those diagnosed with IBS, can be guided by simultaneously measuring changes in select genera in the microbiome.
Resumen de: US2024094224A1
Proxies for physiological states of tissue are provided. Accordingly, there are provided methods of determining host AMP landscape, establishing a profile indicative of tissue status, and identifying proxies for tissue status in AMP profiles of samples of secretions, exudates and/or excretions of the tissue. Also provided are methods for determination of disease severity and chronology.
Resumen de: JP2024037945A
To provide a composition for treatment of inflammatory bowel disease (IBD).SOLUTION: The present invention provides a composition with an anti-TL1A therapeutic agent for treating inflammatory bowel disease (IBD) in subjects whose genotype includes the presence of a single nucleotide polymorphism (SNP) on rs918490, involving the G allele at nuclear position 46338729 (pos_hg19).SELECTED DRAWING: Figure 8C
Resumen de: CN117701702A
The invention relates to the technical field of biological detection, in particular to application of PLCG2 and regulatory pathway related genes thereof in diagnosis and treatment of self-inflammatory diseases. The siRNA is designed and synthesized aiming at the nucleotide sequence of the PLCG2 gene, and after the siRNA is transferred into the human macrophage THP1, the expression of the PLCG2 gene can be efficiently inhibited, and the expression of various inflammatory factors of the THP1 cell can be remarkably reduced, so that the aim of relieving inflammatory symptoms is fulfilled. The PLCG2 siRNA molecule designed by the invention can be used for preparing medicines for treating various self-inflammatory diseases related to PLCG2 function enhancement, including IBD (Infectious Bursal Disease), and has a wide application prospect.
Resumen de: CA3188610A1
The present invention relates to a method of determining the probability that an individual has irritable bowel syndrome and whether the individual will respond to dietary intervention. The present invention also provides a method of determining the probability that an individual with irritable bowel syndrome will respond to dietary intervention. There is also provided the use of a compound as defined herein as a biomarker.
Resumen de: US2024075102A1
Methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) are provided herein.
Resumen de: US2024209103A1
A Provided herein are methods and compositions for patient selection and therapies targeting TL1A. In particular, provided is a method of treating moderate to severely active Crohn's disease (CD) or ulcerative colitis (UC) in a subject, the method comprising: administering a therapeutically effective amount of an inhibitor of Tumor necrosis factor-like cytokine 1A (TL1A) activity or expression to a subject with moderately to severely active CD or UC that has been determined have a polygenetic risk score (PRS) in the 75th percentile, which is indicative of high fold-change of TL1A expression relative to a cut-off fold-change value. Calculating a PRS comprises providing genomic data comprising one or more genotypes (e.g. rs11221332, rs7134599, rs6062496, rs4246905, rs7468800, rs1569328, rs2284553, rs6062504, and rs7556897) of the subject associated with high TL1A fold-change relative to an index or a control.
Resumen de: CN117295952A
The present invention describes biomarkers useful for detecting or diagnosing a disease state, preferably an inflammatory bowel disease state, identifying a treatment regimen for an inflammatory bowel disease, and/or indicating a subject's responsiveness to a treatment regimen for an inflammatory bowel disease. Also described are probes capable of detecting biomarkers and related methods and kits for determining and/or identifying a therapeutic regimen for an inflammatory bowel condition.
Nº publicación: WO2024040289A1 29/02/2024
Solicitante:
ATMO BIOSCIENCES LTD [AU]
ATMO BIOSCIENCES LIMITED
Resumen de: WO2024040289A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject; detecting an ileocecal junction transition indicator among the obtained data, and based on a timing of the detected ileocecal junction transition indicator, detecting a fermentation indicator among the obtained data representing readings preceding the timing of the detected ileocecal junction indicator among the time series of readings; based on the fermentation indicator, determining presence of SIBO in the subject and generating a report indicating the determined presence of SIBO in the subject.
BOPI
Sede Electrónica
